APO Research
Talk to an analyst

APO RESEARCH · REPORT

Obstetrics and Gynecology Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Obstetrics and Gynecology Drugs Market Analysis and Forecast 2026-2032

30 December 2025197 pages

Choose your research edition.

Industry ResearchObstetrics and Gynecology Drugs Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Obstetrics and Gynecology Drugs Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Obstetrics and Gynecology Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Obstetrics and Gynecology Drugs Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Obstetrics and Gynecology Drugs Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Obstetrics and Gynecology Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Obstetrics and Gynecology Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Obstetrics and Gynecology Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Obstetrics and Gynecology Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Obstetrics and Gynecology Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Obstetrics and Gynecology Drugs include Abbott, Johnson & Johnson, Novartis, Merck, Roche, Eli Lilly, Pfizer, Bayer and Amgen, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Obstetrics and Gynecology Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Obstetrics and Gynecology Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Obstetrics and Gynecology Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Obstetrics and Gynecology Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Obstetrics and Gynecology Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Obstetrics and Gynecology Drugs revenue, projected growth trends, production technology, application and end-user industry.

Obstetrics and Gynecology Drugs Segment by Company

Abbott

Johnson & Johnson

Novartis

Merck

Roche

Eli Lilly

Pfizer

Bayer

Amgen

Abbvie

AstraZeneca

TherapeuticsMD

Lupin

GlaxoSmithKline

Ferring

Obstetrics and Gynecology Drugs Segment by Type

Hormonal Therapy

Non-Hormonal Therapy

Obstetrics and Gynecology Drugs Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Obstetrics and Gynecology Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Obstetrics and Gynecology Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Obstetrics and Gynecology Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Obstetrics and Gynecology Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Obstetrics and Gynecology Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Obstetrics and Gynecology Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Obstetrics and Gynecology Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Obstetrics and Gynecology Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Hormonal Therapy Major Player Table 3. Non-Hormonal Therapy Major Player Table 4. Global Obstetrics and Gynecology Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Pharmacies Major Player Table 6. Online Pharmacies Major Player Table 7. Retail Pharmacies Major Player Table 8. Obstetrics and Gynecology Drugs Industry Trends Table 9. Obstetrics and Gynecology Drugs Industry Drivers Table 10. Obstetrics and Gynecology Drugs Industry Opportunities and Challenges Table 11. Obstetrics and Gynecology Drugs Industry Restraints Table 12. Global Obstetrics and Gynecology Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Obstetrics and Gynecology Drugs Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Obstetrics and Gynecology Drugs Market Share by Region (2021-2026) Table 15. Global Obstetrics and Gynecology Drugs Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Obstetrics and Gynecology Drugs Market Share by Region (2027-2032) Table 17. Global Obstetrics and Gynecology Drugs Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Obstetrics and Gynecology Drugs Revenue Market Share by Players (2021-2026) Table 19. Global Obstetrics and Gynecology Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Obstetrics and Gynecology Drugs Key Players Headquarters & Area Served Table 21. Global Obstetrics and Gynecology Drugs Players, Product Type & Application Table 22. Global Obstetrics and Gynecology Drugs Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Obstetrics and Gynecology Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Obstetrics and Gynecology Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Obstetrics and Gynecology Drugs Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Obstetrics and Gynecology Drugs Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Obstetrics and Gynecology Drugs Revenue Market Share by Type (2021-2026) Table 29. Global Obstetrics and Gynecology Drugs Revenue Market Share by Type (2027-2032) Table 30. Global Obstetrics and Gynecology Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Obstetrics and Gynecology Drugs Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Obstetrics and Gynecology Drugs Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Obstetrics and Gynecology Drugs Revenue Market Share by Application (2021-2026) Table 34. Global Obstetrics and Gynecology Drugs Revenue Market Share by Application (2027-2032) Table 35. Abbott Company Information Table 36. Abbott Business Overview Table 37. Abbott Obstetrics and Gynecology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Abbott Obstetrics and Gynecology Drugs Product Portfolio Table 39. Abbott Recent Development Table 40. Johnson & Johnson Company Information Table 41. Johnson & Johnson Business Overview Table 42. Johnson & Johnson Obstetrics and Gynecology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Johnson & Johnson Obstetrics and Gynecology Drugs Product Portfolio Table 44. Johnson & Johnson Recent Development Table 45. Novartis Company Information Table 46. Novartis Business Overview Table 47. Novartis Obstetrics and Gynecology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Novartis Obstetrics and Gynecology Drugs Product Portfolio Table 49. Novartis Recent Development Table 50. Merck Company Information Table 51. Merck Business Overview Table 52. Merck Obstetrics and Gynecology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Merck Obstetrics and Gynecology Drugs Product Portfolio Table 54. Merck Recent Development Table 55. Roche Company Information Table 56. Roche Business Overview Table 57. Roche Obstetrics and Gynecology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Roche Obstetrics and Gynecology Drugs Product Portfolio Table 59. Roche Recent Development Table 60. Eli Lilly Company Information Table 61. Eli Lilly Business Overview Table 62. Eli Lilly Obstetrics and Gynecology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Eli Lilly Obstetrics and Gynecology Drugs Product Portfolio Table 64. Eli Lilly Recent Development Table 65. Pfizer Company Information Table 66. Pfizer Business Overview Table 67. Pfizer Obstetrics and Gynecology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Pfizer Obstetrics and Gynecology Drugs Product Portfolio Table 69. Pfizer Recent Development Table 70. Bayer Company Information Table 71. Bayer Business Overview Table 72. Bayer Obstetrics and Gynecology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Bayer Obstetrics and Gynecology Drugs Product Portfolio Table 74. Bayer Recent Development Table 75. Amgen Company Information Table 76. Amgen Business Overview Table 77. Amgen Obstetrics and Gynecology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Amgen Obstetrics and Gynecology Drugs Product Portfolio Table 79. Amgen Recent Development Table 80. Abbvie Company Information Table 81. Abbvie Business Overview Table 82. Abbvie Obstetrics and Gynecology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Abbvie Obstetrics and Gynecology Drugs Product Portfolio Table 84. Abbvie Recent Development Table 85. AstraZeneca Company Information Table 86. AstraZeneca Business Overview Table 87. AstraZeneca Obstetrics and Gynecology Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. AstraZeneca Obstetrics and Gynecology Drugs Product Portfolio Table 89. AstraZeneca Recent Development Table 90. TherapeuticsMD Company Information Table 91. TherapeuticsMD Business Overview Table 92. TherapeuticsMD Obstetrics and Gynecology Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. TherapeuticsMD Obstetrics and Gynecology Drugs Product Portfolio Table 94. TherapeuticsMD Recent Development Table 95. Lupin Company Information Table 96. Lupin Business Overview Table 97. Lupin Obstetrics and Gynecology Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Lupin Obstetrics and Gynecology Drugs Product Portfolio Table 99. Lupin Recent Development Table 100. GlaxoSmithKline Company Information Table 101. GlaxoSmithKline Business Overview Table 102. GlaxoSmithKline Obstetrics and Gynecology Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. GlaxoSmithKline Obstetrics and Gynecology Drugs Product Portfolio Table 104. GlaxoSmithKline Recent Development Table 105. Ferring Company Information Table 106. Ferring Business Overview Table 107. Ferring Obstetrics and Gynecology Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Ferring Obstetrics and Gynecology Drugs Product Portfolio Table 109. Ferring Recent Development Table 110. North America Obstetrics and Gynecology Drugs Revenue by Type (2021-2026) & (US$ Million) Table 111. North America Obstetrics and Gynecology Drugs Revenue by Type (2027-2032) & (US$ Million) Table 112. North America Obstetrics and Gynecology Drugs Revenue by Application (2021-2026) & (US$ Million) Table 113. North America Obstetrics and Gynecology Drugs Revenue by Application (2027-2032) & (US$ Million) Table 114. North America Obstetrics and Gynecology Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 115. North America Obstetrics and Gynecology Drugs Revenue by Country (2021-2026) & (US$ Million) Table 116. North America Obstetrics and Gynecology Drugs Revenue by Country (US$ Million) & (2027-2032) Table 117. Europe Obstetrics and Gynecology Drugs Revenue by Type (2021-2026) & (US$ Million) Table 118. Europe Obstetrics and Gynecology Drugs Revenue by Type (2027-2032) & (US$ Million) Table 119. Europe Obstetrics and Gynecology Drugs Revenue by Application (2021-2026) & (US$ Million) Table 120. Europe Obstetrics and Gynecology Drugs Revenue by Application (2027-2032) & (US$ Million) Table 121. Europe Obstetrics and Gynecology Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 122. Europe Obstetrics and Gynecology Drugs Revenue by Country (2021-2026) & (US$ Million) Table 123. Europe Obstetrics and Gynecology Drugs Revenue by Country (US$ Million) & (2027-2032) Table 124. China Obstetrics and Gynecology Drugs Revenue by Type (2021-2026) & (US$ Million) Table 125. China Obstetrics and Gynecology Drugs Revenue by Type (2027-2032) & (US$ Million) Table 126. China Obstetrics and Gynecology Drugs Revenue by Application (2021-2026) & (US$ Million) Table 127. China Obstetrics and Gynecology Drugs Revenue by Application (2027-2032) & (US$ Million) Table 128. Asia Obstetrics and Gynecology Drugs Revenue by Type (2021-2026) & (US$ Million) Table 129. Asia Obstetrics and Gynecology Drugs Revenue by Type (2027-2032) & (US$ Million) Table 130. Asia Obstetrics and Gynecology Drugs Revenue by Application (2021-2026) & (US$ Million) Table 131. Asia Obstetrics and Gynecology Drugs Revenue by Application (2027-2032) & (US$ Million) Table 132. Asia Obstetrics and Gynecology Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 133. Asia Obstetrics and Gynecology Drugs Revenue by Region (US$ Million) & (2021-2026) Table 134. Asia Obstetrics and Gynecology Drugs Revenue by Region (US$ Million) & (2027-2032) Table 135. SAMEA Obstetrics and Gynecology Drugs Revenue by Type (2021-2026) & (US$ Million) Table 136. SAMEA Obstetrics and Gynecology Drugs Revenue by Type (2027-2032) & (US$ Million) Table 137. SAMEA Obstetrics and Gynecology Drugs Revenue by Application (2021-2026) & (US$ Million) Table 138. SAMEA Obstetrics and Gynecology Drugs Revenue by Application (2027-2032) & (US$ Million) Table 139. SAMEA Obstetrics and Gynecology Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 140. SAMEA Obstetrics and Gynecology Drugs Revenue by Country (2021-2026) & (US$ Million) Table 141. SAMEA Obstetrics and Gynecology Drugs Revenue by Country (US$ Million) & (2027-2032) Table 142. Research Programs/Design for This Report Table 143. Authors List of This Report Table 144. Secondary Sources Table 145. Primary Sources List of Figures Figure 1. Obstetrics and Gynecology Drugs Image Figure 2. Global Obstetrics and Gynecology Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Obstetrics and Gynecology Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Hormonal Therapy Image Figure 5. Non-Hormonal Therapy Image Figure 6. Global Obstetrics and Gynecology Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Obstetrics and Gynecology Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Pharmacies Image Figure 9. Online Pharmacies Image Figure 10. Retail Pharmacies Image Figure 11. Global Obstetrics and Gynecology Drugs Market Size (US$ Million) & (2021-2032) Figure 12. Global Obstetrics and Gynecology Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Obstetrics and Gynecology Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Obstetrics and Gynecology Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Obstetrics and Gynecology Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Obstetrics and Gynecology Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Obstetrics and Gynecology Drugs Revenue Market Share by Type (2021-2032) Figure 19. Global Obstetrics and Gynecology Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Obstetrics and Gynecology Drugs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Obstetrics and Gynecology Drugs Revenue Market Share by Application (2021-2032) Figure 22. North America Obstetrics and Gynecology Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Obstetrics and Gynecology Drugs Revenue Share by Type (2021-2032) Figure 24. North America Obstetrics and Gynecology Drugs Revenue Share by Application (2021-2032) Figure 25. North America Obstetrics and Gynecology Drugs Revenue Share by Country (2021-2032) Figure 26. United States Obstetrics and Gynecology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Obstetrics and Gynecology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Obstetrics and Gynecology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Obstetrics and Gynecology Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Obstetrics and Gynecology Drugs Revenue Share by Type (2021-2032) Figure 31. Europe Obstetrics and Gynecology Drugs Revenue Share by Application (2021-2032) Figure 32. Europe Obstetrics and Gynecology Drugs Revenue Share by Country (2021-2032) Figure 33. Germany Obstetrics and Gynecology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Obstetrics and Gynecology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Obstetrics and Gynecology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Obstetrics and Gynecology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Obstetrics and Gynecology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Obstetrics and Gynecology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Obstetrics and Gynecology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Obstetrics and Gynecology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Obstetrics and Gynecology Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Obstetrics and Gynecology Drugs Revenue Share by Type (2021-2032) Figure 43. China Obstetrics and Gynecology Drugs Revenue Share by Application (2021-2032) Figure 44. Asia Obstetrics and Gynecology Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Obstetrics and Gynecology Drugs Revenue Share by Type (2021-2032) Figure 46. Asia Obstetrics and Gynecology Drugs Revenue Share by Application (2021-2032) Figure 47. Asia Obstetrics and Gynecology Drugs Revenue Share by Region (2021-2032) Figure 48. Japan Obstetrics and Gynecology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Obstetrics and Gynecology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Obstetrics and Gynecology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Obstetrics and Gynecology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Obstetrics and Gynecology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Obstetrics and Gynecology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Obstetrics and Gynecology Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Obstetrics and Gynecology Drugs Revenue Share by Type (2021-2032) Figure 56. SAMEA Obstetrics and Gynecology Drugs Revenue Share by Application (2021-2032) Figure 57. SAMEA Obstetrics and Gynecology Drugs Revenue Share by Country (2021-2032) Figure 58. Brazil Obstetrics and Gynecology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Obstetrics and Gynecology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Obstetrics and Gynecology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Obstetrics and Gynecology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Obstetrics and Gynecology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Obstetrics and Gynecology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Obstetrics and Gynecology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Obstetrics and Gynecology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Obstetrics and Gynecology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Obstetrics and Gynecology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Obstetrics and Gynecology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Hormonal Therapy
  • Non-Hormonal Therapy
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Abbott
  • Johnson & Johnson
  • Novartis
  • Merck
  • Roche
  • Eli Lilly
  • Pfizer
  • Bayer
  • Amgen
  • Abbvie
  • AstraZeneca
  • TherapeuticsMD
  • Lupin
  • GlaxoSmithKline
  • Ferring

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Obstetrics and Gynecology Drugs Market by Type
  3. 1.2.1 Global Obstetrics and Gynecology Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Hormonal Therapy
  5. 1.2.3 Non-Hormonal Therapy
  6. 1.3 Obstetrics and Gynecology Drugs Market by Application
  7. 1.3.1 Global Obstetrics and Gynecology Drugs Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital Pharmacies
  9. 1.3.3 Online Pharmacies
  10. 1.3.4 Retail Pharmacies
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Obstetrics and Gynecology Drugs Market Dynamics
  1. 2.1 Obstetrics and Gynecology Drugs Industry Trends
  2. 2.2 Obstetrics and Gynecology Drugs Industry Drivers
  3. 2.3 Obstetrics and Gynecology Drugs Industry Opportunities and Challenges
  4. 2.4 Obstetrics and Gynecology Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Obstetrics and Gynecology Drugs Market Perspective (2021-2032)
  2. 3.2 Global Obstetrics and Gynecology Drugs Growth Trends by Region
  3. 3.2.1 Global Obstetrics and Gynecology Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Obstetrics and Gynecology Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global Obstetrics and Gynecology Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Obstetrics and Gynecology Drugs Revenue by Players
  2. 4.1.1 Global Obstetrics and Gynecology Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global Obstetrics and Gynecology Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Obstetrics and Gynecology Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Obstetrics and Gynecology Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Obstetrics and Gynecology Drugs Key Players Headquarters & Area Served
  7. 4.4 Global Obstetrics and Gynecology Drugs Players, Product Type & Application
  8. 4.5 Global Obstetrics and Gynecology Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Obstetrics and Gynecology Drugs Market CR5 and HHI
  11. 4.6.3 2025 Obstetrics and Gynecology Drugs Tier 1, Tier 2, and Tier 3
5 Obstetrics and Gynecology Drugs Market Size by Type
  1. 5.1 Global Obstetrics and Gynecology Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Obstetrics and Gynecology Drugs Revenue by Type (2021-2032)
  3. 5.3 Global Obstetrics and Gynecology Drugs Revenue Market Share by Type (2021-2032)
6 Obstetrics and Gynecology Drugs Market Size by Application
  1. 6.1 Global Obstetrics and Gynecology Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Obstetrics and Gynecology Drugs Revenue by Application (2021-2032)
  3. 6.3 Global Obstetrics and Gynecology Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Abbott
  2. 7.1.1 Abbott Company Information
  3. 7.1.2 Abbott Business Overview
  4. 7.1.3 Abbott Obstetrics and Gynecology Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Abbott Obstetrics and Gynecology Drugs Product Portfolio
  6. 7.1.5 Abbott Recent Developments
  7. 7.2 Johnson & Johnson
  8. 7.2.1 Johnson & Johnson Company Information
  9. 7.2.2 Johnson & Johnson Business Overview
  10. 7.2.3 Johnson & Johnson Obstetrics and Gynecology Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Johnson & Johnson Obstetrics and Gynecology Drugs Product Portfolio
  12. 7.2.5 Johnson & Johnson Recent Developments
  13. 7.3 Novartis
  14. 7.3.1 Novartis Company Information
  15. 7.3.2 Novartis Business Overview
  16. 7.3.3 Novartis Obstetrics and Gynecology Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Novartis Obstetrics and Gynecology Drugs Product Portfolio
  18. 7.3.5 Novartis Recent Developments
  19. 7.4 Merck
  20. 7.4.1 Merck Company Information
  21. 7.4.2 Merck Business Overview
  22. 7.4.3 Merck Obstetrics and Gynecology Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Merck Obstetrics and Gynecology Drugs Product Portfolio
  24. 7.4.5 Merck Recent Developments
  25. 7.5 Roche
  26. 7.5.1 Roche Company Information
  27. 7.5.2 Roche Business Overview
  28. 7.5.3 Roche Obstetrics and Gynecology Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Roche Obstetrics and Gynecology Drugs Product Portfolio
  30. 7.5.5 Roche Recent Developments
  31. 7.6 Eli Lilly
  32. 7.6.1 Eli Lilly Company Information
  33. 7.6.2 Eli Lilly Business Overview
  34. 7.6.3 Eli Lilly Obstetrics and Gynecology Drugs Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Eli Lilly Obstetrics and Gynecology Drugs Product Portfolio
  36. 7.6.5 Eli Lilly Recent Developments
  37. 7.7 Pfizer
  38. 7.7.1 Pfizer Company Information
  39. 7.7.2 Pfizer Business Overview
  40. 7.7.3 Pfizer Obstetrics and Gynecology Drugs Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Pfizer Obstetrics and Gynecology Drugs Product Portfolio
  42. 7.7.5 Pfizer Recent Developments
  43. 7.8 Bayer
  44. 7.8.1 Bayer Company Information
  45. 7.8.2 Bayer Business Overview
  46. 7.8.3 Bayer Obstetrics and Gynecology Drugs Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Bayer Obstetrics and Gynecology Drugs Product Portfolio
  48. 7.8.5 Bayer Recent Developments
  49. 7.9 Amgen
  50. 7.9.1 Amgen Company Information
  51. 7.9.2 Amgen Business Overview
  52. 7.9.3 Amgen Obstetrics and Gynecology Drugs Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Amgen Obstetrics and Gynecology Drugs Product Portfolio
  54. 7.9.5 Amgen Recent Developments
  55. 7.10 Abbvie
  56. 7.10.1 Abbvie Company Information
  57. 7.10.2 Abbvie Business Overview
  58. 7.10.3 Abbvie Obstetrics and Gynecology Drugs Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Abbvie Obstetrics and Gynecology Drugs Product Portfolio
  60. 7.10.5 Abbvie Recent Developments
  61. 7.11 AstraZeneca
  62. 7.11.1 AstraZeneca Company Information
  63. 7.11.2 AstraZeneca Business Overview
  64. 7.11.3 AstraZeneca Obstetrics and Gynecology Drugs Revenue and Gross Margin (2021-2026)
  65. 7.11.4 AstraZeneca Obstetrics and Gynecology Drugs Product Portfolio
  66. 7.11.5 AstraZeneca Recent Developments
  67. 7.12 TherapeuticsMD
  68. 7.12.1 TherapeuticsMD Company Information
  69. 7.12.2 TherapeuticsMD Business Overview
  70. 7.12.3 TherapeuticsMD Obstetrics and Gynecology Drugs Revenue and Gross Margin (2021-2026)
  71. 7.12.4 TherapeuticsMD Obstetrics and Gynecology Drugs Product Portfolio
  72. 7.12.5 TherapeuticsMD Recent Developments
  73. 7.13 Lupin
  74. 7.13.1 Lupin Company Information
  75. 7.13.2 Lupin Business Overview
  76. 7.13.3 Lupin Obstetrics and Gynecology Drugs Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Lupin Obstetrics and Gynecology Drugs Product Portfolio
  78. 7.13.5 Lupin Recent Developments
  79. 7.14 GlaxoSmithKline
  80. 7.14.1 GlaxoSmithKline Company Information
  81. 7.14.2 GlaxoSmithKline Business Overview
  82. 7.14.3 GlaxoSmithKline Obstetrics and Gynecology Drugs Revenue and Gross Margin (2021-2026)
  83. 7.14.4 GlaxoSmithKline Obstetrics and Gynecology Drugs Product Portfolio
  84. 7.14.5 GlaxoSmithKline Recent Developments
  85. 7.15 Ferring
  86. 7.15.1 Ferring Company Information
  87. 7.15.2 Ferring Business Overview
  88. 7.15.3 Ferring Obstetrics and Gynecology Drugs Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Ferring Obstetrics and Gynecology Drugs Product Portfolio
  90. 7.15.5 Ferring Recent Developments
8 North America
  1. 8.1 North America Obstetrics and Gynecology Drugs Revenue (2021-2032)
  2. 8.2 North America Obstetrics and Gynecology Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America Obstetrics and Gynecology Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America Obstetrics and Gynecology Drugs Revenue by Type (2027-2032)
  5. 8.3 North America Obstetrics and Gynecology Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America Obstetrics and Gynecology Drugs Revenue by Application (2021-2032)
  7. 8.4.1 North America Obstetrics and Gynecology Drugs Revenue by Application (2021-2026)
  8. 8.4.2 North America Obstetrics and Gynecology Drugs Revenue by Application (2027-2032)
  9. 8.5 North America Obstetrics and Gynecology Drugs Revenue Share by Application (2021-2032)
  10. 8.6 North America Obstetrics and Gynecology Drugs Revenue by Country
  11. 8.6.1 North America Obstetrics and Gynecology Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Obstetrics and Gynecology Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America Obstetrics and Gynecology Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Obstetrics and Gynecology Drugs Revenue (2021-2032)
  2. 9.2 Europe Obstetrics and Gynecology Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe Obstetrics and Gynecology Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe Obstetrics and Gynecology Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe Obstetrics and Gynecology Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe Obstetrics and Gynecology Drugs Revenue by Application (2021-2032)
  7. 9.4.1 Europe Obstetrics and Gynecology Drugs Revenue by Application (2021-2026)
  8. 9.4.2 Europe Obstetrics and Gynecology Drugs Revenue by Application (2027-2032)
  9. 9.5 Europe Obstetrics and Gynecology Drugs Revenue Share by Application (2021-2032)
  10. 9.6 Europe Obstetrics and Gynecology Drugs Revenue by Country
  11. 9.6.1 Europe Obstetrics and Gynecology Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Obstetrics and Gynecology Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe Obstetrics and Gynecology Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Obstetrics and Gynecology Drugs Revenue (2021-2032)
  2. 10.2 China Obstetrics and Gynecology Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China Obstetrics and Gynecology Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China Obstetrics and Gynecology Drugs Revenue by Type (2027-2032)
  5. 10.3 China Obstetrics and Gynecology Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China Obstetrics and Gynecology Drugs Revenue by Application (2021-2032)
  7. 10.4.1 China Obstetrics and Gynecology Drugs Revenue by Application (2021-2026)
  8. 10.4.2 China Obstetrics and Gynecology Drugs Revenue by Application (2027-2032)
  9. 10.5 China Obstetrics and Gynecology Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Obstetrics and Gynecology Drugs Revenue (2021-2032)
  2. 11.2 Asia Obstetrics and Gynecology Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia Obstetrics and Gynecology Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia Obstetrics and Gynecology Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia Obstetrics and Gynecology Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia Obstetrics and Gynecology Drugs Revenue by Application (2021-2032)
  7. 11.4.1 Asia Obstetrics and Gynecology Drugs Revenue by Application (2021-2026)
  8. 11.4.2 Asia Obstetrics and Gynecology Drugs Revenue by Application (2027-2032)
  9. 11.5 Asia Obstetrics and Gynecology Drugs Revenue Share by Application (2021-2032)
  10. 11.6 Asia Obstetrics and Gynecology Drugs Revenue by Country
  11. 11.6.1 Asia Obstetrics and Gynecology Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Obstetrics and Gynecology Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia Obstetrics and Gynecology Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Obstetrics and Gynecology Drugs Revenue (2021-2032)
  2. 12.2 SAMEA Obstetrics and Gynecology Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Obstetrics and Gynecology Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Obstetrics and Gynecology Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA Obstetrics and Gynecology Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Obstetrics and Gynecology Drugs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Obstetrics and Gynecology Drugs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Obstetrics and Gynecology Drugs Revenue by Application (2027-2032)
  9. 12.5 SAMEA Obstetrics and Gynecology Drugs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Obstetrics and Gynecology Drugs Revenue by Country
  11. 12.6.1 SAMEA Obstetrics and Gynecology Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Obstetrics and Gynecology Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Obstetrics and Gynecology Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst